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Myosin phosphatase and RhoA-
activated kinase modulate arginine 
methylation by the regulation of 
protein arginine methyltransferase 
5 in hepatocellular carcinoma cells
Adrienn Sipos1, Judit Iván1,2, Bálint Bécsi1,2, Zsuzsanna Darula3, István Tamás1, 
Dániel Horváth1, Katalin F. Medzihradszky3, Ferenc Erdődi1,2 & Beáta Lontay1
Myosin phosphatase (MP) holoenzyme is a protein phosphatase-1 (PP1) type Ser/Thr specific enzyme 
that consists of a PP1 catalytic (PP1c) and a myosin phosphatase target subunit-1 (MYPT1). MYPT1 
is an ubiquitously expressed isoform and it targets PP1c to its substrates. We identified the protein 
arginine methyltransferase 5 (PRMT5) enzyme of the methylosome complex as a MYPT1-binding 
protein uncovering the nuclear MYPT1-interactome of hepatocellular carcinoma cells. It is shown that 
PRMT5 is regulated by phosphorylation at Thr80 by RhoA-associated protein kinase and MP. Silencing 
of MYPT1 increased the level of the PRMT5-specific symmetric dimethylation on arginine residues of 
histone 2 A/4, a repressing gene expression mark, and it resulted in a global change in the expression of 
genes affecting cellular processes like growth, proliferation and cell death, also affecting the expression 
of the retinoblastoma protein and c-Myc. The phosphorylation of the MP inhibitory MYPT1T850 and the 
regulatory PRMT5T80 residues as well as the symmetric dimethylation of H2A/4 were elevated in human 
hepatocellular carcinoma and in other types of cancers. These changes correlated positively with the 
grade and state of the tumors. Our results suggest the tumor suppressor role of MP via inhibition of 
PRMT5 thereby regulating gene expression through histone arginine dimethylation.
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is a leading cause of 
cancer-related deaths. The molecular mechanism behind the pathogenesis of HCC is poorly understood, although 
molecular markers and more precise classification would be crucial1. One of the potential therapeutic target 
mechanisms is reversible protein phosphorylation at serine (Ser) and threonine (Thr) residues by the coordinated 
action of protein kinases and phosphatases. More than 98% of cellular protein phosphorylation occurs at Ser/Thr2 
and it regulates intracellular signal transduction pathways resulting in profound changes in cellular responses. 
Many protein kinases are identified as oncogenes and protein dephosphorylation by protein phosphatases may 
also play a critical role in malignant transformation of cells3. Protein phosphatase-1 (PP1) is one representative of 
the major phospho-Ser/Thr (P-Ser/Thr) specific eukaryotic protein phosphatases. Mammalian genomes contain 
three different genes that encode five distinct PP1 catalytic subunits (PP1c): PP1cα1/a2, PP1cβ/δ and PP1cγ1/γ24. 
Several lines of evidence suggest that PP1 activity is required for exit from mitosis, yet may also block cell cycle 
progression and facilitate apoptosis5. Moreover, okadaic acid, a potent and specific inhibitor of PP1 and protein 
phosphatase 2 A (PP2A) enzymes was described as a powerful tumor promoter that triggers tumor formation in 
various organs such as liver6. Previous studies reported that the nuclear PP1cα and PP1cβ /δ activity significantly 
decreased in human HepG2 and rat AH13 hepatoma cells compared with primary cultured hepatocytes also 
suggesting that PP1 is a tumor suppressor in its own right5.
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It is assumed that free PP1c is not present in the cells, but it performs its diverse biological activities by form-
ing holoenzymes with one of the almost 200 PP1c-binding proteins, termed targeting/inhibitory subunits, in a 
mutually exclusive manner7. The functions of these proteins are to target PP1c to the substrate, to modulate the 
enzyme activity and to determine the subcellular localization8. Myosin phosphatase target subunit 1 (MYPT1) 
is one of the regulatory proteins that binds to PP1c to form a highly stable holoenzyme referred to as myosin 
phosphatase (MP). MP is a heterotrimer composed of the β /δ isoform (termed both ways) of PP1c and two 
non-catalyic subunits, MYPT1 and a 20 kDa subunit with essentially unknown function9. It is the dominant form 
in smooth muscle but is expressed ubiquitously in mammalian tissues10. Much of the earlier works have focused 
on smooth muscle MP, which regulates the phosphorylation level of the 20 kDa regulatory light chains of myosin 
II, thereby mediating contractile and motile events in these cells11. Although numerous cytoskeletal MP substrates 
have been identified so far12 suggesting its role in cell migration and metastasis formation, MYPT1 was also found 
in the nuclear and microsomal fraction of HepG2 cells13, and in the nucleus of neuronal cells14. MP plays impor-
tant roles in nucleus related cellular processes, including mitosis by antagonizing polo-like kinase-115, apoptosis 
by dephosphorylating and facilitating the nuclear localization of the histone deacetylase protein and repression 
of Nur77, a proapoptotic gene16. MP also inhibits oncogenic signaling cascades by modulating the dephospho-
rylation of merlin tumor suppressor protein, which regulates the Ras-signaling extracellular signal-regulated 
kinase (ERK) pathway driving tumorigenic transformation17. MP also modulates the dephosphorylation of the 
retinoblastoma protein, which plays a role in G1/S transition of cell cycle18. Moreover, MYPT1 KO mice develops 
a lethal phenotype indicating the crucial role of MP in cell proliferation and gene expression19. Thus, the above 
data suggest that dysregulation of phosphorylation signaling pathways related to MP is directly correlated with a 
plethora of diseases such as cancer and diabetes.
One of the potential regulatory pathways related to MP function is driven by the RhoA GTPase and its 
downstream Ser/Thr kinase termed RhoA-activated kinase (ROK) which was shown to phosphorylate MYPT1 
at Thr696 and Thr850, thereby causing inhibition of MP activity20. Although Thr696 of MYPT1 can be phos-
phorylated by other kinases, the Thr850 (by human sequence) inhibitory phosphorylation site is dominantly 
regulated by ROK21. Additionally, numerous other downstream targets of ROK have been identified including 
intermediate filaments, adducin and the dephosphorylation of these substrates at the ROK-specific phosphoryl-
ation site are catalyzed by MP22. It was shown that initiation of HCC formation23 is mediated by ROK and hyper-
activation of RhoA/ROK is associated with aggresive tumors with enhanced metastatic features in numerous 
organs24. Moreover, Y27632, the selective inhibitor of ROK suppresses invasiveness of several animal cancers such 
as HCC25. A plethora of studies have suggested that ROK inhibitors might be drug candidates in the treatment of 
cancer by targetting stromal cells rather than tumor cells26.
To elucidate the contribution of the ROK/MP axis in tumorigenesis beyond their already described role in 
angiogenesis and metastasis our goal was to describe the nuclear function of MP. Our present data indicate a 
potential tumorsuppressor role for MP in human hepatocarcinoma cells via antagonizing the tumorigenic effect 
of ROK. Our results shed light on the involvement of ROK/MP enzyme pair in the phosphorylation/dephospho-
rylation of the protein arginine methyltransferase 5 (PRMT5) via regulating arginine methylation of histones 
thereby affecting signaling for cancer formation.
Results
MYPT1 nuclear interactome: interaction with PRMT5 of the methylosome complex. Initial 
reports have already described the presence of MYPT1 in the nucleus but its exact subnuclear localization and 
function remained unknown13. MYPT1, PP1cα /γ 1 and PP1cδ were distributed in the cytoplasmic and nuclear 
subcellular fractions (Fig. S1A). Specific activity measured in the presence of 2 μ M inhibitor-2 (I2) which is a 
highly selective inhibitor of PP1, but does not influence PP2A activity27 suggested that ~60% of total phosphatase 
activity of nuclear fraction was due to PP1 (Fig. S1B). Myosin phosphatase was found to be localized to the chro-
matin and the spliceosomes in the nucleus of HepG2 cells (Fig. S1C). To gain more data for the role of MP, we 
determined the nuclear interactome of Flag (FT)-MYPT1 by mass spectrometry. Pull-down assays were carried 
out using FT-MYPT1 protein bound to anti-Flag M2 affinity gel which was incubated with the nuclear extract 
of HepG2 cells. The FT-MYPT1 binding proteins were eluted from the beads, separated by SDS-PAGE then the 
protein bands were silver-stained, excised and subjected to LC-MS/MS analysis. Twenty-two potential MYPT1-
interacting proteins were identified (Table 1). The peptide sequences identified are presented in Table S1 together 
with the percentage distribution for cellular roles of their parent proteins (Table S2). Nuclear MYPT1-binding 
proteins may play roles in RNA processing and splicing and in gene expression (Table 1). Mitogen-activated 
protein kinase and magnesium-dependent protein phosphatase 1B (PP1B/PP2C) were also among the potential 
interacting partners of MYPT1. Strikingly, the protein arginine methyltransferase 5 (PRMT5/JBP1), the member 
of the methylosome complex was also identified. PRMT5 is one of the nine PRMTs in mammalian cells and plays 
an unique and specific role in the generation of the ω -NG, NG-symmetric dimethylarginine (SDMA) as a type II 
PRMT. It has multiple cytosolic and nuclear binding partners and is implicated in the regulation of transcription, 
RNA transport and cellular signaling28.
PRTM5 of the methylosome complex interacts with MP through the N-terminal region in 
MYPT1. Since PRMT5 was identified as a nonspecific interacting protein in affinity purified Flag-tagged 
complexes from HeLa and tsa cell lysates29, we verified the interaction between the nuclear PRMT5 and MYPT1 
with additional methods. Anti-MYPT11-296 and anti-PRMT5 antibodies were used to immunoprecipitate target 
proteins and a possible association between MYPT1 and PRMT5 was assayed in HepG2 cells (Fig. 1A). PRMT5 
and MYPT1 were identified in each precipitates as judged by Western blots implying that these two proteins 
were co-precipitated. No cross reactions were detected in the non-immune serum control (Fig. 1A). Surface 
plasmon resonance (SPR)-based binding assays were carried out to investigate the molecular background of 
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MYPT1-PRMT5 interaction using full-length GST-MYPT1 as well as a GST-fusion C-terminal fragment of 
residues 667 to 1004 (GST-MYPT1667-1004). These MYPT1 species were bound on SPR sensorchips to immobi-
lized anti-GST and purified FT-PRMT5 was flown through the flow cells as an analyte. PRMT5 formed a stable 
complex with the full-length GST-MYPT11-1004 in a concentration range of 0.3125–5 μ M and the association 
constant for binding was Ka = (1.62 ± 0.29) × 107 M−1 (Fig. 1B), while no signal for binding was obtained with 
GST-MYPT1667-1004 (data not shown). Fitting the sensograms with a 1:1 binding model resulted in overlaps with 
the experimental curves suggesting a 1. 1 molar ratio in the GST-MYPT11-1004- PRMT5 complex formed. These 
data demonstrate also that PRMT5 forms a stable interaction with the N-terminal region of MYPT1.
PRMT5 is a substrate of ROK and MP and its methyltransferase activity is regulated via 
phosphorylation/dephosphorylation of its Thr80 residue. The putative phosphorylation sites of 
PRMT5 were screened and the identities of protein kinases that may target these sites were predicted by a P-Si 
NCBI gi# Protein MW, Da Peptide number Function
4505317 Protein phosphatase 1 regulatory subunit 12 A isoform a (MYPT1) 115610 20 Signal transduction
13699824 Kinesin family member 11 120111 7 Motor protein, mitosis
338443 Beta-spectrin 275259 3 Protein targeting
20070220 Protein arginine methyltransferase 5 isoform a 73322 8 Transcription regulation
4507361 Mitogen-activated protein kinase kinase kinase 7 isoform A 64930 3 Signal transduction, transcription regulation
4506583 Replication protein A1 68723 2 DNA replication, DNA damage
4505995 Protein phosphatase 1B isoform 1 53180 6 Signaling pathways, cell stress response pathways
307383 RNA helicase A 143405 3 Translation initiation, splicing, spliceosome assembly
29881667 Splicing factor proline/glutamine-rich 76255 8 Splicing
11067747 CDC5-like protein 92422 2 Cell cycle control, transcription regulation
288100 Initation factor 4B 69240 2 Translation initiation
4885225 Ewing sarcoma breakpoint region 1 isoform 2 68721 2 Gene expression, cell signaling, RNA processing
693937 Polyadenylate binding protein II 58709 12 Gene expression, RNA processing
56237027 Insulin-like growth factor 2 mRNA binding protein 1 isoform 1 63783 2 Translation regulation, mRNA transport
4504447 Heterogeneous nuclear ribonucleoprotein A2/B1 isoform A2 36041 3 Gene expression, mRNA processing
4504445 Heterogeneous nuclear ribonucleoprotein A1 isoform a 34289 2
mRNS processing and transport, RNA 
splicing
356168 Histone H1b 21721 2 DNA-binding, nucleosome assembly
Table 1.  FT-MYPT1 binding proteins of HepG2 nuclear fraction.
Figure 1. Interaction of MYPT1 with PRMT5. (A) Immunoprecipitations were carried out using 
anti-MYPT11-296 and anti-PRMT5 antibodies as well as nonimmune rabbit serum as negative control. 
Immunoprecipitates and HepG2 total lysate were analysed by Western blots using antibodies specific for 
MYPT1 and PRMT5. (B) SPR analysis of the interaction of MYPT1 with PRMT5. Full-length GST-MYPT11-1004 
was immobilized on anti-GST coupled CM5 sensor chip. FT-PRMT5 was injected over the surfaces in the 
indicated concentrations. The interaction was monitored using Biacore 3000. The association constant (Ka) 
value was indicated in the figure.
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Figure 2. ROK and MP regulate the methyltransferase activity of PRMT5 through phosphorylation/
dephosphorylation at Thr80. (A) Autoradiograms of PRMT5 phosphorylated in the absence or in the 
presence of 0.1 μ g/ml protein kinase A (PKA, left panel), 0.1 μ g/ml protein kinase C (PKC, middle panel) 
or 0.4 U/ml Rho-associated kinase (ROK, right panel) with 32P-ATP. (B) Western blot analysis of ROK-
phosphorylated PRMT5 using antibody specific for phospho-Thr. After stripping the membrane anti-PRMT5 
antibody was applied to detect PRMT5 as an input control. (C) Ion trap collision-induced dissociation (CID) 
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Predictor alogrithm developed by Kinexus (http://www.phosphonet.ca/). Protein kinase A (PKA), protein kinase 
C (PKC) and ROK were suggested as potential phosphorylating enzymes therefore they were probed in in vitro 
phosphorylation assays. The autoradiogram in Fig. 2A shows that PRMT5 was phosphorylated by ROK but not 
by PKA or PKC in kinase assays when radioactive ATP (γ - 32P-ATP) was used as phosphoryl donor substrate. 
Western blot analysis of ROK-phosphorylated PRMT5 by antibody specific for phosphorylated Thr (Fig. 2B) indi-
cated that ROK phosphorylates PRMT5 definitely on Thr residue. Thr80 residue was identified as a ROK phos-
phorylation site in PRMT5 by mass spectometry analysis of ROK-phosphorylated FT-PRMT5 samples compared 
to non-phosphorylated ones (Fig. 2C). Ser15/16, Thr67 were Ser69 were also identified as potential phosphoryl-
ation sites of PRMT5 from LC-MS/MS data. However, only Thr80 phosphorylation was unambiguously linked 
to the ROK-treatment since the phosphorylation of Ser15/16 was also identified in control samples which were 
incubated without ROK and the Thr67 and Ser69 phosphorylation sites were infirm even after the enrichment 
using titanium-oxide chromatography (Fig. S6.).
ROK-specific phosphorylation of PRMT5T80 was confirmed by ROK-assay (Fig. 2D, Fig. S3A) in which the 
relative Thr80 phosphorylation level of wild type PRMT5 determined by anti-phospho-PRMT5T80 antibody 
(anti-pPRMT5T80) was significantly decreased in the presence of H1152, a selective Rho-kinase inhibitor. Alanine 
mutant of PRMT5T80 (PRMT5T80A) was generated by site-directed mutagenesis and phosphorylation of this 
mutant was probed in ROK assay in the presence and absence of H1150. As judged with anti- anti-PPRMT5T80 
antibody on Western blot no signal was detected confirming the Thr80 specificity of ROK in PRMT5 phospho-
rylation (Fig. S3B).
To prove the regulatory role of MP on PRMT5, FT-PRMT5 was phosphorylated by ROK and in vitro phos-
phatase assays were carried out using recombinant PP1cδ and purified FT-MYPT1 proteins or their combination 
representing MP holoenzyme (Fig. 2E). Western blot data using anti-pPRMT5T80 showed that the FT-MYPT1 
had no effect on the phosphorylation level of PRMT5 at Thr80, whereas recombinant PP1cδ or the mixture of 
PP1cδ and FT-MYPT1 caused ~14% and ~40% decrease in phospho-PRMT5T80, respectively comparing to the 
ROK-phosphorylated samples. The increased dephosphorylation of PRMT5 at Thr80 by PP1cδ in presence of 
FT-MYPT1 indicates that the phosphorylated PRMT5 is a substrate of MP holoenzyme and MYPT1 has a target-
ing role in this dephosphorylation process.
To determine the effect of the phosphorylation of PRMT5 at Thr80 on its methyltransferase activity we assayed 
PRMT5 activity by determining symmetric dimethylation of histone 2A and 4 (H2A and H4) on their common 
arginine 3, the so called “R3 motif ”30. No significant changes in symmetrical dimethylation of H2AR3 or H4R3 
were detected when FT-MYPT1 without PP1cδ was used (Fig. 2H and I). Nevertheless, in accordance with the 
rate of PRMT5-dephosphorylation represented in Fig. 3G symmetrical dimethylation of H4R3 was decreased 
by 15% and 46% when PP1cδ and the mixture of FT-MYPT1 and PP1cδ was applied during methyltransferase 
assay. Changes in the symmetrical dimethylation level of H2AR3 (Fig. 2F) were even more profound, 23% adding 
PP1cδ and 67% adding the mixture of PP1cδ and FT-MYPT1. Since MEP50 is an essential component of the 
methyltransferase activity of PRMT5, we tested if the phosphorylation at Thr80 increases the affinity of MEP50 to 
PRMT5 resulting the enhanced activity upon ROK phosphorylation. The phosphorylation by ROK with or with-
out the inhibition of ROK by H1152 had no effect on the amount of the MEP50 bound to the wt PRMT5 (Fig. 2F.). 
The relative amount of MEP50 binding to wt PRMT5 showed no significant differences either upon ROK phos-
phorylation or the dephosphorylation by MP (Fig. 2G.) suggesting that the phosphorylation of PRMT5 at Thr80 
has no effect on MEP50 binding. These data indicate that Thr80 residue is a regulatory phosphorylation site of 
PRMT5 and the phosphorylation increases, while the dephosphorylation decreases its methytransferase activity.
Silencing of MYPT1 increased H2A and H4 Arg3 dimethylation and PRMT5 phosphorylation at 
Thr80 in HepG2 cells. Histone 2AR3 and − 4R3 are symmetrically dimethylated by PRMT5 which shifts the 
balance from an activating asymmetric (ADMA) to a suppressive symmetric dimethylarginine (SDMA) mark at 
these motifs with respect to gene expression31. The fact that MP dephosphorylated PRMT5 at the ROK-specific 
phosphorylation site in vitro led us to examine whether MP plays a role in the regulation of gene expression 
through the arginine methylation of H2A and 4 at the gene repression sites in vivo. We first transfected HepG2 
cells with MYPT1-specific siRNAs (siMYPT1) or non-targeting siRNA as a control. SiMYPT1 was able to lower 
spectra of PRMT5 phosphopeptides. CID of m/z: 656.338 (3+ ) identified as SDLLLSGRDWNpTLIVGK 
representing [69–85] of the wild type protein. Thr80 was identified as the modification site (see fragment ion 
y11 (phosphorylated)). Peptide fragments are labeled according to the nomenclature by Biemann56. (D) Effect 
of ROK inhibitor (10 μ M H1152) on the phosphorylation level of PRMT5 during in vitro ROK assay. Control 
samples were prepared in the absence of ROK, positive control samples were prepared in the presence of 
ROK without ROK inhibitor. Relative phosphorylation level of Thr80 was judged by Western blot using anti- 
pPRMT5T80 antibody and blots for PRMT5 served as loading control. (E) Effect of 25 nM FT-MYPT1 and 5 nM 
rPP1cδ or their combination on the phosphorylation level of PRMT5 at Thr8080 as judged by Western blot. 
Data were compared to ROK-phosphorylated PRMT5. (F,G) Amount of MEP50 bound to FT-PRMT5 during 
ROK-phosphorylation (F) and dephosphorylation by MP (G) compared to unphosphorylated control samples. 
MEP50 was detected by anti-MEP50 antibody during Western blot and relative amount was normalized to the 
level of PRMT5. (H,I) In vitro arginine methyltransferase assay of unphosphorylated and ROK-phosphorylated 
PRMT5 measured by the symmetric dimethylation level of histone H2A Arg3 (H2AR3me2s, F) or histone H4 
Arg3 (H4R3me2s, G) in the presence of 25 nM FT-MYPT1, 5 nM rPP1cδ or their combinations. Gels have been 
processed under the same experimental conditions. Values represents mean ± SEM; **p < 0.01, ***p < 0.001, 
****p < 0.0001, #p < 0.05, one-way ANOVA followed by Tukey’s multiple comparison test, n = 3.
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Figure 3. Effect of MYPT1 silencing on the methyltransferase activity of PRMT5 in HepG2 cells. 
Immunofluorescent staining of non-target control (Ctrl) and MYPT1-silenced (siMYPT1) cells using  
antibodies specific for MYPT11-296 (A), PRMT5 (B), histone H2A symmetric dimethyl Arg3 (H2AR3me2s  
(C) and histone H4 symmetric dimethyl Arg3 (H4R3me2s (D) and actin as inducated in the figures. Scale 
bars: 50 μ M. Enlargement of framed regions in merged images are shown on the right on A, B, C and D panels. 
Nuclear fractions of non-target control (Ctrl) and MYPT1-silenced (siMYPT1) HepG2 cells were prepared 
and analysed by Western blot using anti-MYPT11-296 (E), anti-PRMT5 (F), anti-pPRMT5T80 (G), anti-histone 
H2A symmetric dimethyl Arg3 (H) and anti-histone H4 symmetric dimethyl Arg3 (I) specific antibodies. 
The relative expression of MYPT1 or PRMT5 and the relative symmetric dimethylation level of H2AR3 or 
H4R3 were normalized to lamin A/C as internal control. Samples derived from the same experiment and the 
blots were processed in parallel or assayed after stripping. The relative phosphorylation level of PRMT5T80 
was normalized to the expression level of PRMT5 and then to lamin A/C as internal control by densitometry. 
Mean ± SEM; n = 3; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by student t-test.
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the protein expression of MYPT1 by > 70% (Fig. 3E) without causing any significant decrease either in the sur-
vival (Fig. S4A) or the caspase-3 activity (Fig. S4B) as signs for apotosis of HepG2 cells. Upon MYPT1-silencing 
drastic changes in cell morphology and in formation of stress fibers were detected by immunofluorescent staining 
(Fig. 3A). PRMT5 was localized to the cytosolic as well as to the nuclear fraction (Fig. 3B). MYPT1-silencing 
had no effect on either the protein expression (Fig. 3F) or on the subcellular localization of PRMT5, however, 
the phosphorylation of PRMT5 at Thr80 was increased by 46% (Fig. 3G). Moreover, we examined the effect 
of siMYPT1 on the level of dimethylation of H2AR3 (Fig. 3H) and H4R3 (Fig. 3I) and it was elevated by 40% 
and 45%, respectively, whereas the expression of both histone proteins remained constant. The fluorescence 
intensity of the dimethylation of H2AR3 (Fig. 3C) and H4R3 (Fig. 3D) increased followed by MYPT1-silencing. 
Fluorescent mean intensity of H2AR3 symmetrical dimethylation increased from 12.8 to 21.79 (arbitrary unit) 
due to MYPT1-silencing. Difference in symmetrical dimethylation was more considerable in case of H4R3 (from 
8.19 to 22.58) compared to non-significant intensity changes of H2A or H4 expression (Table S6). To verify our 
data we applied the nuclear extract of non-target and MYPT1-silenced HepG2 and MCF7 cells on quantitative 
methyltransferase assay (Fig. S5A and B). Knocking down MYPT1 increased the specific activity of PRMT5 by 
~65% comparing to the control samples. Taken together, our results reflect the physiological regulatory role of MP 
in the methyltransferase activity of PRMT5 and thus influence the dimethylation of histone respression marks.
Silencing of MYPT1 results in altered gene expression pattern and downregulates the expression 
of tumor suppressors in HepG2 cells. To more precisely define the role of MP in functions related to the 
regulation of dimethylation of histone proteins, we performed microarray studies using the Affymetrix Human 
Gene 1.0 ST Array for the analysis of gene expression. Over 39,000 transcripts/single array were examined 
encompassing the entire expressed human genome. Total RNA was isolated from control and MYPT1-silenced 
(siMYPT1) HepG2 cells (Fig. 4). The comparison of control and siMYPT1 samples identified 2728 genes differ-
entially regulated between the two groups. Complete lists of genes are available at www.figshare.com website. 
Table S7 shows a list of genes that were up- or downregulated by more than 1.5-fold (n = 3) in the siMYPT1 sam-
ples when compared to gene expression pattern. Hierarchical cluster analysis was performed on all differentially 
expressed genes using average linkage with Pearson’s dissimilarity and the number of induced and repressed 
genes were presented in a heat map (Fig. 4A). Bioinformatic analysis was assigned to different canonical pathways 
such as LPS/IL-1 mediated inhibition of RXR function (PPAR α , γ , IL1R, JUN), antioxidant action of vitamin C 
(STAT5, MAPK3 and 9), cell cycle regulation (Not7, PPP2C, CDK2, E2F3, Rb protein) as well as IL-4 and IL-8 
signaling. Knocking down of MYPT1 also influenced molecular and cellular functions such as lipid metabolism, 
molecular transport, cell growth and differentiation and cell death. Additionally, the siMYPT1-related genes were 
analyzed for identifying diseases and disorders relevant to the list. Strikingly, 36% of all related genes (960) were 
linked to cancer disease such as lymphohematopoietic, liver and breast cancer and renal-cell carcinoma for-
mation. Genes related to infectious diseases and developmental disorders were also identified in 10% and 6%, 
respectively. Taken together, microarray analysis identified a number of signaling pathways strongly point to a 
role of MP in the regulation of gene expression.
The evaluation of genes related to MYPT1-silencing revealed the significant downregulation of several tumor 
suppressors and transcription factors. One of them is the retinoblastoma protein (pRb) that plays a pivotal role in 
the negative control of the cell cycle and in tumor progression as a major regulator of G1 checkpoint32. The other 
is c-Myc that regulates the cell cycle progression and cellular transformation as a multifunctional transcription 
factor33. The protein expressions of pRb and c-Myc were significantly decreased upon MYPT1 silencing and these 
were also confirmed by Western blot analysis (Fig. 4C and D). To clarify fully the connection between the MP 
activity and the PRMT5-regulated gene expression we screened for genes related to both PRMT5 and MP in the 
database of the siPRMT534 and siMYPT1 microarray analysis, respectively. Rap1 gene expression was 2.3 fold 
reduced upon PRMT5 silencing in human embryonic stem cells and the expression of this gene was found to be 
significantly increased in siMYPT1 cells (Fig. 4E).
Myosin phosphatase is involved in the regulation of gene expression through the suppression 
mark of PRMT5 on histone 2A and 4 in human cancer. The microarray analysis indicated that in case 
of decreased level of MP cancer-related processes dominate. Reverse phase protein microarray analysis was con-
ducted in multiple tissue lysates of patients for the validation of changes in the protein levels and their posttrans-
lational modifications in cancer. Tumor tissue lysates obtained from a large group of human patients with grade 
2 and 3 and state II and III (Fig. 5 dark grey columns) hepatocellular carcinoma (n = 20), four different types of 
metastatic liver cancers (Fig. 5 light grey columns) as well as 15 other types of cancer cell lines with their adequate 
normal cell type controls (Fig. 5 black columns) were analysed using high throughput screening for multiple 
protein targets such as PRMT5 (Fig. 5A), pPRMT5T80 (Fig. 5B), MYPT1 (Fig. 5C), pMYPT1T850 (Fig. 5D), histone 
2A (Fig. 5E) and histone 2A symmetric arginine methylation (Fig. 5F).
The protein expression of PRMT5 showed an increase in ~75% of the investigated cancer tissues comparing to 
the healthy controls. THP-1 monocytic leukemia and Raji Burkitt lyphomoma cells presented the largest increase 
(Fig. 5A). The relative phosphorylation of PRMT5 at Thr80 in cancer tissues were significantly elevated in all 
cases escpecially in the leukemia, lung, colon and breast cancer carcinoma as well as in HCC tissues (Fig. 5B). The 
relative MYPT1 expression exhibited a diverse expression pattern since it was significantly downregulated in few 
cases (HeLa cervix and A549 lung carcinoma) but in uterine carcinoma it showed a twofold increase. However, 
MYPT1 expression did not change in the majority of cancer types (65%). Since MP holoenzyme activity is reg-
ulated through the phosphorylation of MYPT1 at the Thr850 inhibitory site, we were able to draw conclusions 
about the activity of PP1M in tumor cells based on the phosphorylation state of MP. Increased phosphorylation 
level of MYPT1Thr850 was found in almost all cases up to a 10–12-fold elevation in breast and lung carcinomas 
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(Fig. 5D). The overexpression of histone proteins in cancer cells and the elevated symmetric dimethylation of 
them have been already described in colorectal, glioblastoma and numerous other cancer types35,36. We also 
verified either no changes (Burkitt lymphoma, hepatocellular adenomatoid and trabecular adenocarcinoma) or 
significant elevation in histone protein expression (Fig. 5E) and 85% of all examined cancer types showed an 
increase in the repressive Arg3 symmetrical dimethylation mark. Our results imply that the decreased activity of 
MP bears an obvious relation to the increased activity of PRMT5 and the increased gene repression mark on his-
tones in almost every investigated cancer types particularly in bladder and colon carcinoma, MCF7 breast cancer, 
THP1 monocytic leukemia, kidney adenocarcinoma and in hepatocellular carcinoma. Except for the expression 
Figure 4. Microarray analysis of MYPT1-silenced HepG2 cells. (A) Heat map of genes related to MYPT1 
silencing in HepG2 cells by microarray analysis. The color code for the signal strength is shown in the box at the 
bottom in which induced genes are indicated by red and repressed genes are indicated by blue. (B) The onthology 
of the related genes and their classification by GO terms. Detection of retinoblastoma protein (C) and c-Myc 
(D) protein expression changes due to MYPT1 silencing from HepG2 whole cell lysates by Western blot. Protein 
levels were quantified by densitometry normalized to α -tubulin or GAPDH expression level. Samples derived 
from the same experiment and processed in parallel. RT-PCR analysis of MYPT1, PRMT5 and RAP1A mRNA 
levels in non-specific siRNA treated and MYPT1 silenced HepG2 cells (E). GAPDH was used as an invariant 
gene. Values are mean ± SEM from three independent experiments; *p < 0.05, **p < 0.01 by student t-test.
www.nature.com/scientificreports/
9Scientific RepoRts | 7:40590 | DOI: 10.1038/srep40590
of MYPT1 in all other cases, the protein expression as well as the phosphorylation of PRMT5 at Thr80, and the 
arginine methylation of histone 2A and 4 increased in the higher grade and stage in hepatocellular carcinoma 
tissues (n = 11–13) exhibiting a strong correlation to the grade and state of the tumor. These data suggest the 
involvement of the ROK/MP/PRMT5/histone dimethylation pathway in tumorigenesis.
Discussion
In the present study we have characterized a novel mechanism of tumorigenesis governed by ROK and MP in 
hepatocarcinoma cells (HCC). We have identified Thr80 in PRMT5 as the target of ROK/MP and the phos-
phorylation/dephosphorylation of this site is shown to modulate the activity of PRMT5. At high phosphoryl-
ation of PRMT5 at Thr80 symmetric dimethylation of the histone R3-motif is preferred which accompanied 
Figure 5. Protein expression profile of HCC and other cancer cell lines. Reverse phase protein microarray 
analysis was conducted to study the changes in protein expression and posttranslational modification of PRMT5 
(A,B), MYPT1 (C,D) and histone H2A (E,F) proteins in normal and tumor human cell lysates. Human HCC 
samples (n = 20) were grouped based on their clinically verified stage (middle grey columns) or grade (dark 
grey columns) classification of tumor. Average of HCC samples irrespectively of grouping and other types of 
metastatic liver cancer tissues are shown next to each other (light grey columns). Protein microarray contains 
15 cancer cell lines and normal tissue lysate of controls of corresponding organs in triplicates (black columns). 
Value of 1 means average of relative expression, phosphorylation or symmetrical dimethylation of the given 
protein or residue to the corresponding non-tumor samples. Blots were processed under the same experimental 
procedure. Datas are mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by student t-test.
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by tumorogenesis, while dephosphorylation by MP has an opposite effect. Therefore, MP could be assumed as 
a tumorsuppressor in HCC. The interplay between MP and PRMT5 is also supported by interaction analysis. 
First, the presence of PRMT5 in the MYPT1 nuclear interactome is appealing for an interacting protein complex. 
Second, SPR-based in vitro binding assay identified a stable interaction between MYPT1 (the large targeting sub-
unit of MP) and PRMT5 and it was verified that PRMT5 binds to the N-terminal region of MYPT1.
Our findings show that ROK/MP counteract on the Thr80 phosphorylation site of PRMT5 regulating its 
methyltransferase activity both in vitro (Fig. 2) and in vivo (Fig. 3). The PRMT5 protein includes multiple tyrosyl 
and seryl/threonyl residues that could be potentially targeted by phosphorylation. PRMT5 can be phosphorylated 
by a constitutively active janus kinase 2 mutant at the tyrosyl 304 and 307 residue resulting in the disruption of the 
interaction between MEP50 and PRMT5 and the inhibition of the activity of PRMT5 in patients with myoprolif-
erative neuroplasm37. The ROK/MP regulated Thr80 residue and its surrounding peptide sequences are not part 
of the methyltransferase domain of PRMT5 and play no role in the formation of the heterooctameric structure of 
PRMT54:MEP504 based on the crystal structure of human PRMT538. PRMT5T80 is located in a peptide sequence 
(GRDWNTLI/VV) well conserved among vertebrates but not in invertebrate orthologs. Furthermore, PRMT5 
exhibits no sequence homology with PRMT1-4 enzymes39 suggesting a selective regulatory function of its phos-
phorylation at Thr80. The fact that PRMT5-Thr80 phosphorylation increases the activity of the enzyme without 
the recruitment of more MEP50 into the complex supports the hypothesis that this modification triggers changes 
either in the substrate- or in the S-adenosylmethionine methyl donor binding sites. Our findings provide a yet 
unrecognized signaling mechanism which regulates PRMT5 activity directly with posttranslational modification.
Histone tail modifications are major components of the epigenetic regulation of gene transcription. It is well 
established that PRMT5 has preference for the symmetrical dimethylation of H4R3, H2AR3 and H3R8 shift-
ing the balance to a suppressive mark40,31. The symmetrically dimethylated R3-motif recruites the DNA methyl-
transferase DNMT3A to chromatin domains via its ADD domain to suppress gene expression thus representing 
epigenetic silencing of gene expression41. We provided several lines of evidence that silencing of MYPT1 results 
in a global change in gene expression through the activation of PRMT5 and by the indirect modulation of the 
“R3-motifs” of H2A and H4. Moreover, the general assumption that PRMT5 functions as a transcriptional core-
pressor is not definite since symmetric-dimethyl-arginine-containing protein(s) can specifically associate with 
the IL-2 promoter after T-cell activation and increase gene expression42. Our observation that cancer-related 
pathways are upregulated in HCC upon MYPT1 silencing is the results of the higher expression and hyperactiva-
tion of PRMT5, which suppresses gene and protein expression of several tumor suppressors or increasing that of 
potential oncogenes. First, the tumor suppressor pRb expression was significantly decreased in siMYPT1 HepG2 
cells suggesting the anti-tumor role of MYPT1 in HCC. This is well in line with the findings that PRMT5 overex-
pression triggered the suppression of the transcription of the pRb in leukemia and in lymphoma cell43. Second, 
c-Myc as a global transcriptional regulator can activate genes involved in cell proliferation and growth but it is also 
able to repress genes involved in cell cycle and adhesion44 raising the possibility of a yet-unexplored mechanism 
used by tumors to suppress differentiation and potentiate agressiveness. C-Myc expression is significantly lower 
in HCC than in nontumor tissues and is inversely proportional to the grade of differentiation45. We found that 
MYPT1 silencing resulted in a decrease in c-Myc gene and protein expression suggesting again the tumorsuppres-
sor effect of this MP subunit, and presumably MP itself, in HCC. Finally, we also found that Rap1, one of the target 
genes induced by PRMT534 was upregulated in siMYPT1 HepG2 cells (Fig. 5E). Rap1 functions as a genomwide 
transcriptional regulator and a critical player in tumor malignancy. The fact that inhibition of Rap1 interfered 
with tumor development and induced higher apoptosis rates46 also suggest that silencing of MYPT1 mimicks the 
protein expression pattern of cancer cells and the tumor suppressor activity of MYPT1 and therefore MP.
Previous studies speculated that constant and unbalanced phosphorylation of MYPT1 at Thr850 might be 
related to cancer formation47. Based on the phosphorylation of MYPT1T850 we confirmed that the activity of the 
nuclear MP decreased, the activity of PRMT5 phophorylated at Thr80 increased and PRMT5-specific repressive 
R3-dimethylation increased in HCC and in other cancer cell lines suggesting the fundamental role of this path-
way in tumorigenesis. Since both the stage and the grade of the tumors were directly related to the activity of this 
pathway, we hypothesized that this is an action governed by ROK. The downregulation of RhoA, an upstream 
activator of ROK48 and the direct inhibition of ROK by Incarvine C and Y27632 decreased the phosphorylation 
of MYPT1 at Thr850 in lung cancer and HCC49, respectively, and the ROK-phosphorylated MYPT1 was localized 
not only in the cytoplasm but in the nucleus as well50.
PRMT5 was overexpressed in multiple tumor types including leukemia, lymphoma, lung27, colorectal 
and breast cancer as well as in HCC and it resulted in increased symmetrical dimethylation on H2A and H4 
R3-motifs35. The prognosis of patients with HCC is associated with the expression level of PRMT5. The overex-
pression of PRMT5 increased the symmetric dimethylation of histone R3 motifs and we provided evidence that it 
is related to the enhanced phosphorylation level of PRMT5 at Thr80 (Fig. 6).
In this study we have provided new insights into the regulation of tumor suppressor pathways demonstrating 
that MP is a negative regulator of the PRMT5 oncoprotein. MP possesses a dual function in cancer-related path-
ways as it is not only a cytoskeletal regulator governing cell migration and metastasis but it also functions as a key 
regulator of gene expression and has anti-tumor features. Taken together, the “MP/PRMT5/histone R3” pathway 
plays a critical role in tumorigenesis and cancer development, therefore the pharmacological interventions of this 
pathway by targeting MP may have important and promising clinical implications in therapeutics.
Material and Methods
Chemicals and antibodies. All chemicals were obtained from Sigma Aldrich unless otherwise indicated. 
Antibodies used are listed in the Supplementary Information Materials and Methods section. Buffer compositions 
are described in Supplementary Materials.
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Recombinant proteins. PP1cδ , GST-MYPT11-1004 and GST-MYPT1667-1004 were expressed in E. coli and 
purified as described before51,52. FT-PRMT5 (Sino Biological) for SPR and phosphorylation assays for MS analysis 
was free from MEP50 (Fig. S2C). FT-PRMT5wt (FT-PRMT5wt), -PRMT5T80A and FT-MYPT1 was purified from 
transfected tsA201 lysates using anti-Flag M2 affinity gel (Sigma Aldrich) applying the manufacturer’s protocol. 
FT-PRMT5wt and -PRMT5T80A proteins were bound to anti-Flag M2 affinity gel during kinase and phosphatase 
assays and in vitro protein arginine methyltransferase assays. FT-PRMT5 was in complex with MEP50 (Fig. S2C). 
PP1c-free FT-MYPT1 was produced for the execution of phosphatase assays and in vitro protein arginine meth-
yltransferase assays. The FT-MYPT1 bound to the anti-Flag M2 affinity gel was incubated with MYPT11-296 pep-
tide13 several times to dissociate the PP1c subunit then FT-MYPT1 was eluted from the beads with 300 μ g/ml 
Flag-peptide (Sigma Aldrich). The lack of PP1c in the FT-MYPT1 preparation was validated by Western blot with 
anti-PP1c antibody and phosphatase assay with 32P-MLC20 substrate, The purity of all the PP1cδ (Fig. S2D), 
GST-MYPT11-1004 and GST-MYPT1667-1004 (Fig. S2A) were jugjed by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PASGE).
Cell cultures, transient transfections and silencing of MYPT1. HepG2 cells and human embryonal 
kidney (tsA201) cells from The European Collection of Cell Cultures were grown as described13. All materi-
als used for cell culture were purchased from PAA Laboratories, AustriaThe endogenous MYPT1 protein level 
was knocked down using double-stranded siRNAs (Table S5, Thermo Scientific Inc.) and a non-target sequence 
(ON-TARGETplus Non-targeting siRNA #1 from Thermo Scientific Inc.) with the G–C content of siMYPT1 
sequences was used as a control. TsA201 cells were transfected with pReceiver-M11 plasmids for overexpression. 
Protocols are detailed in the Supplementary Methods. The cell lysis and protein measurement were performed as 
described before14.
HepG2 fractionation method. HepG2 cells were grown to 80% confluency, washed with ice-cold PBS, 
collected and centrifuged at 4 °C at 1,500 × g for 3 min. After the removal of PBS cells were homogenized in 400 μ l 
buffer A by suspending with a 26 gauge needle 10 times using a 1 ml syringe. The lysate was vortexed for 15 sec. 
The efficiency of lysis was judged by trypan blue staining monitoring intact nuclei. The lysate was centrifuged 
at 4 °C at 16,000 × g for 1 min and the supernatant was used as cytosolic fraction. The pellet was resuspended 
in 200 μ l buffer A and passed through the 26G needle 10 times as a washing step. After centrifugation at 4 °C at 
16,000 × g for 1 min 100 μ l buffer B was added to the pellet and sonicated and used as nuclear fraction.
Cell viability and caspase assays. HepG2 cells were grown in 96-well plates to determine viability by 
MTT assay and caspase-3 activity and were carried out as detailed before53.
Immunoblotting. SDS-PAGE and immunoblotting were carried out as describe previously13. For quantita-
tive comparisons samples derived from the same experiments. For quantification of PRMT5-Thr80 phosphoryla-
tion membranes were stripped and assayed for PRMT5 content as it is described on the Supplementary Methods. 
Internal controls were either assayed on the same gel or were processed in parallel. Densitometry of the proteins 
of interest were performed by Image J. 1.46 and normalized to an internal control protein and plotted as relative 
numbers as detailed in figure legends.
Immunofluorescence microscopy. HepG2 cells were grown on rat tail collagen-coated coverslips (BD 
Biosciences) and fixed using 4% paraformaldehyde and treated as described53. Primary and secondary antibodies 
Figure 6. MP plays a tumorsuppressor role and antagonizes ROK in HCC. We hypothesize that MP and 
ROK are involved in gene expression. Under normal conditions MP modulates symmetrical dimethylation of 
histone core proteins in cell nucleus via dephosphorylation of PRMT5 at its activatory phosphorylation site 
(Thr80) causing changes in gene expression. In tumor cells inhibitory phosphorylation of MP on Thr850 is 
increased leading to higher phosphorylation level of PRMT5 at Thr80 by ROK. Activated PRMT5 provokes gene 
repression by raising symmetrical dimethylation of histone H4 Arg3 that triggers proto-oncogene activation 
and tumor formation.
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were applied in 1:100 and 1:200 dilutions, respectively. DAPI (1:2000) were added as a nuclear marker as indi-
cated in figure legends. Images were taken by Leica X8 confocal microscope and were processed using Leica X8 
software program and PhotoShop Imaging software.
Surface Plasmon resonance (SPR). SPR-based binding studies were carried out using a Biacore 3000 
instrument to monitor the interaction of MYPT1 with PRMT5. GST-MYPT11-1004 and GST-MYPT1667-1004 were 
immobilized on anti-GST coupled CM5 sensorchip54. FT-PRMT5 was injected over the surfaces in various con-
centrations and the responses recorded. Binding of FT-PRMT5 was characterized by kinetic parameters and 
association constant (Ka) values determined by BIAevaluation 3.1 software.
Site-directed mutagenesis. Expression vector pReceiver-M11 encoding wild-type human full-length 
PRMT5 (NM_006109.3) transcript variant 1 was purchased from GeneCopoeia Inc., USA. Point mutations of 
PRMT5T80A in pReceiver-M11 were performed using QuickChange II XL Site-Directed Mutagenesis Kit accord-
ing to the manufacturer’s instructions (Agilent Technologies). Primer pairs are listed in Table S3. The sequence of 
mutants were verified by DNA sequencing, primers are listed in Table S4.
Immunoprecipitation and pull-down assays. For LC-MS/MS analysis of FT-MYPT1 interacting pro-
teins FT-MYPT1 and Flag-peptide as control were bound to anti-Flag M2 affinity gel. The samples were pre-
cleared on the anti-Flag M2 affinity gel prior to affinity isolation. After washing with Tris-buffered saline solution 
(TBS) three times, beads were incubated with HepG2 nuclear extract for 2 hr on 4 °C. The FT-MYPT1 was 
eluted with 300 μ g/ml Flag-peptide from the beads with the anchored proteins. Eluted samples were subjected to 
SDS-PAGE. Bands of interest were visualized by MS compatible silver staining and the proteins were subjected 
to in-gel digestion using trypsin. No proteins other than human keratin contamination were identified from the 
control samples.
For immunoprecipitation (IP) anti-MYPT1-296 and -PRMT5 antibodies were incubated with Protein-A 
Sepharose (GE Healthcare) as described before14. The blots were developed with anti-MYPT1-296and anti-PRMT5 
antibodies followed by Clean-blot IP detection reagent (HRP).
In vitro protein arginine methyltransferase assay. FT-PRMT5wt was bound to anti-Flag M2 
affinity gel following phosphorylation by protein kinases and was applied for the methylation assay. 2 μ M 
S-adenosyl-L-methionine and 0.02 mg/ml of histone mixture from calf thymus (Roche) were added to the reac-
tion in a total volume of 50 μ l. Methylation reaction was allowed to proceed for 2 hours at 30 °C in the presence 
or in the absence of 5 nM recombinant PP1cδ 51, 25 nM FT-MYPT1 or the combination of PP1cδ and FT-MYPT1 
(assumed as MP holoenzyme). Products of the methylation reactions were analysed by Western blots using anti-
bodies specific for symmetrical dimethylation of H2A Arg3 and H4 Arg3. Membranes were stripped on 50 °C for 
30 min in stripping buffer in every case and were assayed with anti-H2A and anti-H4 antibodies as input controls. 
Changes of symmetrical dimethylation levels were calculated by densitometry normalized to histone H2A and 
histone H4 internal controls. Methyltransferase assay was also carried out with colorimetric Epigenase PRMT 
methyltransferase type II-specific assay kit (Epigentech) following the instructions of the manufacturer.
Protein kinase and protein phosphatase assays. Phosphorylation of recombinant human PRMT5 
(Sino Biological Inc.) was initiated by 0.2 mM 32P-ATP or for LC-MS/MS analysis by 0.5 mM ATP in the absence 
(control) or in the presence of 0.4 U/ml ROK (Upstate, Millipore), 0.1 μ g/ml PKA or 0.1 μ g/ml PKC at 30 °C for 
120 min. ROK was applied in buffer C and all kinase assay buffers contained 1 μ M mycrocystin-LR (MC-LR). 
PKA and PKC assay buffer are described in Supplementary Methods. The reaction mixtures were subjected to 
SDS-PAGE and bands were detected by autoradiography or visualized by MS/MS compatible silver staining and 
were cut out and subjected to LC-MS/MS analysis.
Phosphorylation reaction by ROK (0.4 U/ml) was also carried out in the absence or in the presence of 10 μ M 
H1152 with 0.5 mM ATP, 5mM MgCl2 and 1 μ M MC-LR at 30 °C using FT-PRMT5wt bound to anti-Flag 
M2 affinity gel. After 15 min incubation kinase assay medium was removed and beads were washed by TBS. 
Dephosphorylation of ROK-phosphorylated FT-PRMT5wt bound to the beads (the product of the kinase assay) 
was initiated by adding 25 nM FT-MYPT1, 5 nM rPP1cδ or the combination of these two proteins at 30 °C for 
15 min, then the beads were washed by TBS and the bound (eluted??) proteins were subjected to SDS-PAGE. 
Bands were detected by autoradiography or visualized by MS/MS compatible silver staining. Bands of PRMT5 
were cut out and subjected to in-gel digestion using trypsin. Approximately 80% of the peptide mixtures were 
subjected to phosphopeptide enrichment using TiO255, then the phosphopeptide fractions as well as the remain-
ing 20% of the original samples were analyzed by data-dependent LC-MS/MS using an Orbitrap Elite mass spec-
trometer (MS spectra acquired in the Orbitrap, MS/MS spectra in the linear ion trap). Phosphorylation level of 
Thr80 of PRMT5 was detected by phospho-PRMT5T80 specific antibody on Western blots and analysed by densi-
tometry normalized to the PRMT5 input using Image J. (NIH) software.
Gene expression analysis. Total RNA was extracted from non-target control and MYPT1 silenced HepG2 
cells using TRIzol reagent (Invitrogen) as described in the manufacturer’s protocol. NanoDrop ND-1000 spectro-
photometer (Thermo Scientific) was used to determine the RNA concentration. RNA was treated with RNase free 
DNase I (Thermo Scientific) and reverse transcription was performed with qPCRBIO cDNA synthesis kit (PCR 
Biosystems). PCR amplification was carried out with Maxima Hot Start PCR Master Mix (Thermo Scientific) 
based on manufacturer’s protocol. RT-PCR products were analyzed by agarose gel electrophoresis. The expression 
level of the genes of interest were performed by Image J. 1.46, normalized to GAPDH and represented as relative 
numbers. The primer pairs used in the RT-PCR experiments are summarized in Table S8.
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Microarray processing and data analysis. Expression pattern of non-target and MYPT1 silenced HepG2 
cells was examined and analysed as detailed before53 using total RNA extracted as described in the previous sec-
tion. Statistically significant difference was considered at p < 0.05 and fold change cut off value was 1.5.
LC-MS/MS analysis. Bands of interest were subjected to in-gel digestion using side-chain protected porcine 
trypsin (37 °C, 4 h) [http://msf.ucsf.edu/ingel.html]. For the identification of MYPT1 interacting proteins, the 
resulting peptide mixtures were analyzed directly by data-dependent „triple play” LC-MS/MS using a 3D-ion trap 
mass spectrometer (LCQ-Fleet, Thermo). Identification of MYPT1 interacting proteins and the PRMT5 phospho-
rylation sites from LC-MS/MS data were detailed in the Supplementary Methods section.
Tissue array analysis. SomaPlex reverse phase protein microarray slides containing human liver and nor-
mal tissue samples from 25 clinical cases and 15 common cancer cell line lysates in triplicates were purchased 
from Protein Biotechnologies. Microarray slides were handled following the manufacturer’s instructions as 
detailed in Supplementary Methods. Dots of interest were analysed by densitometry and were all normalized to 
their adequate tubulin internal control. Values of the phosphorylation of PRMT5 at Thr80, -MYPT at Thr850 and 
H2AR3me2s were normalized to PRMT5, MYPT and H2A, respectively. Values of cancer tissues were related to 
normal tissue data and plotted as relative numbers.
Statistical analysis. Normalized data were analyzed using either Student’s t-test (for two groups) or analysis 
of variance (one-way ANOVA, for > 2 groups). Post hoc testing for one-way ANOVA was determined by Tukey’s 
test. Parametric statistical tests were used if the assumptions of such tests were met. All normalized variables 
used in statistical analyses were found to be normally distributed. Tests were conducted using GraphPad for 
Windows. All data presented in this work represent mean ± SEM, n means the number of independently per-
formed experiments.
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